Evidence map›Paper›PMID 26809457›Full record

ArticlePsychopharmacology2016

The effects anandamide signaling in the prelimbic cortex and basolateral amygdala on coping with environmental stimuli in rats.

Mano Aliczki, Istvan Barna, Ibolya Till, Maria Baranyi, Beata Sperlagh, Steven R Goldberg, Jozsef Haller

Abstract read
PubMed Publisher
In one paragraph

Article in Psychopharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Role of endocannabinoids in the hippocampus and amygdala in emotional memory and plasticity.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018
    Article
  4. Prefrontal endocannabinoids, stress controllability and resilience: A hypothesis.Progress in neuro-psychopharmacology & biological psychiatry · 2018
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mano AliczkiDepartment of Behavioural Neurobiology, Institute of Experimental Medicine, Hungarian Academy of Sciences, 1450, Budapest, P.O. Box 67, Hungary.
Istvan BarnaDepartment of Behavioural Neurobiology, Institute of Experimental Medicine, Hungarian Academy of Sciences, 1450, Budapest, P.O. Box 67, Hungary.
Ibolya TillDepartment of Behavioural Neurobiology, Institute of Experimental Medicine, Hungarian Academy of Sciences, 1450, Budapest, P.O. Box 67, Hungary.
Maria BaranyiDepartment of Pharmacology, Institute of Experimental Medicine, Hungarian Academy of Sciences, Budapest, Hungary.
Beata SperlaghDepartment of Pharmacology, Institute of Experimental Medicine, Hungarian Academy of Sciences, Budapest, Hungary.
Steven R GoldbergPreclinical Pharmacology Section, Behavioral Neuroscience Research Branch, Intramural Research Program, Department of Health and Human Services, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA.
Jozsef HallerDepartment of Behavioural Neurobiology, Institute of Experimental Medicine, Hungarian Academy of Sciences, 1450, Budapest, P.O. Box 67, Hungary. haller@koki.hu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleSeveral lines of recent evidence suggest that endocannabinoids affect behavior by influencing the general patterns of challenge responding.

objectivesHere, we investigated the brain mechanisms underlying this phenomenon in rats.

methodsThe anandamide hydrolysis inhibitor URB597 was condensed into the tip of stainless steel cannulae, which were chronically implanted slightly above the prelimbic cortex (PRL) or the basolateral amygdala (BLA), two important regions of coping and endocannabinoid action. Thereafter, we investigated behavioral responsiveness to ambient light level in the elevated plus-maze and conditioned fear tests.

resultsURB597 concentration was ~30 μg/mg protein in target areas; local brain anandamide levels increased threefold, without significant changes in 2-arachidonoylglycerol. High levels of illumination halved the time spent by controls in the open arms of the plus-maze. No similar decrease was observed in rats with URB597 implants in the PRL. High light decreased conditioned fear by 30 % in controls, but not in rats with prelimbic URB597 implants. Unresponsiveness to environmental challenges was not attributable to the anxiolytic effects of anandamide enhancement, as implants induced paradoxical anxiogenic-like effects under low light, which could be explained by effects on stimulus responsiveness rather than by effects on anxiety. URB597 implants targeting the BLA did not affect stimulus responsiveness.

conclusionsOur findings show that elevated prelimbic anandamide signaling leads to less environment-dependent (more autonomous) behavioral responses to challenges, which is an attribute of active coping styles. These findings are discussed in light of two emerging concepts of endocannabinoid roles, particularly "emotional homeostasis" and "active coping."

Indexed as

Adaptation, PsychologicalAnimalsAnti-Anxiety AgentsAnxietyArachidonic AcidsBasolateral Nuclear ComplexBenzamidesCarbamatesEndocannabinoidsGlyceridesMalePolyunsaturated AlkamidesPrefrontal CortexRatsRats, WistarSignal TransductionanandamideAnti-Anxiety AgentsArachidonic AcidsBenzamidesCarbamatescyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl esterEndocannabinoidsGlyceridesPolyunsaturated AlkamidesAmygdalaAnandamideBasolateral amygdalaCopingEmotional homeostasisMedial prefrontal cortexPrelimbic cortexURB597

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.